A detailed history of National Bank Of Canada transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, National Bank Of Canada holds 919 shares of BMRN stock, worth $59,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares
919
Previous 919 -0.0%
Holding current value
$59,054
Previous $64,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$69.02 - $93.84 $929,285 - $1.26 Million
-13,464 Reduced 93.61%
919 $64,000
Q2 2024

Aug 02, 2024

SELL
$74.43 - $92.22 $15.6 Million - $19.3 Million
-209,522 Reduced 93.58%
14,383 $1.18 Million
Q1 2024

May 13, 2024

SELL
$83.81 - $99.0 $3.75 Million - $4.43 Million
-44,702 Reduced 16.64%
223,905 $19.6 Million
Q4 2023

Feb 06, 2024

SELL
$76.22 - $98.51 $26.1 Million - $33.7 Million
-342,304 Reduced 56.03%
268,607 $25.9 Million
Q3 2023

Oct 10, 2023

BUY
$85.07 - $94.48 $50.4 Million - $56 Million
592,585 Added 3233.58%
610,911 $54.1 Million
Q2 2023

Jul 26, 2023

BUY
$86.68 - $100.3 $900,171 - $1.04 Million
10,385 Added 130.78%
18,326 $1.59 Million
Q1 2023

Apr 12, 2023

SELL
$87.74 - $117.27 $63,260 - $84,551
-721 Reduced 8.32%
7,941 $772,000
Q4 2022

Jan 24, 2023

SELL
$80.93 - $108.63 $146,078 - $196,077
-1,805 Reduced 17.24%
8,662 $0
Q3 2022

Oct 13, 2022

SELL
$82.16 - $96.94 $222,817 - $262,901
-2,712 Reduced 20.58%
10,467 $907,000
Q2 2022

Jul 28, 2022

SELL
$71.48 - $86.85 $1.14 Million - $1.39 Million
-16,014 Reduced 54.86%
13,179 $1.12 Million
Q1 2022

May 05, 2022

BUY
$74.28 - $92.69 $1.29 Million - $1.61 Million
17,352 Added 146.54%
29,193 $2.3 Million
Q4 2021

Jan 24, 2022

BUY
$71.72 - $91.47 $849,236 - $1.08 Million
11,841 New
11,841 $1.03 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.9B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.